Feasibility of Early Gabapentin as an Intervention for Neurorecovery

Drug

General health

Online since 3 November 2022, updated 820 days ago

About this trial

This is a trial enrolling individuals with recent (less than five days) traumatic spinal cord injuries to test the feasibility of using a drug on recovery. The drug, Gabapentin, is commonly used in spinal cord injury to manage neuropathic pain. Different doses of Gabapentin will be administered for 90 days. If included, participants will receive either a low dose of Gabapentin, a high dose of Gabapentin, or a placebo for comparison. Final testing will be performed after 6 months.

Included participants

Gender

All

Age

≥ 18 years

Injury level

C1 - S5

Time since injury

≥ null null

Injury type

Traumatic

Healthy volunteers

C1-S5

Additionally, participants must

NOT have suffered a moderate/severe traumatic brain injury (TBI)

What’s involved

Type

Drug

Details

- Oral intake of two capsules, three times a day, for 90 days

Potential benefits

Main benefits

General health

Additional benefits

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results